New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
06:18 EDTUTHRUnited Therapeutics announces Japan approval for Remodulin
United Therapeutics announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin Injection for the treatment of pulmonary arterial hypertension, or PAH, by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost by Mochida Pharmaceutical, under an exclusive distribution agreement with United Therapeutics.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
16:21 EDTUTHROn The Fly: Closing Wrap
Subscribe for More Information
13:05 EDTUTHRUnited Therapeutics price target raised to $141 from $133 at Wedbush
Subscribe for More Information
12:53 EDTUTHRCourt ruling in Remodulin patent case favors United Therapeutics
Subscribe for More Information
12:49 EDTUTHRStocks with increasing volume options volume
Stocks with increasing volume options volume: OXY HD RSH UTHR IRF TTWO CONN
12:18 EDTUTHROn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTUTHRHigh option volume stocks
Subscribe for More Information
10:51 EDTUTHRUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use